Hyderabad Startup Harnesses AI & Nanotechnology to Advance Autoimmune Skin Disorders & Wound Care
Advertisement
The startup says it employed AI algorithms to analyse extensive botanical databases and used three-dimensional molecular modelling to virtually screen thousands of plant-derived compounds and nanotechnology to encapsulate these bioactive compounds.
A Hyderabad-based biotech startup has combined artificial intelligence, nanotechnology and biomedical research to develop and commercialise therapies targeting autoimmune skin disorders and wound care.
Incubated at the BRIC-Centre for DNA Fingerprinting and Diagnostics (BRIC-CDFD) Technology Incubator, Acubiosys has positioned its AI-driven approach as a way to develop safer, targeted and evidence-based treatments for chronic skin conditions.
Dr Srinivas Maddi, Founder and CEO of Acubiosys, said, “Our vision is to bridge artificial intelligence, nanotechnology and life sciences to develop affordable, science-backed healthcare solutions that address unmet medical needs. By combining cutting-edge research with translational innovation, we aim to deliver accessible therapies that improve patient outcomes while contributing to India’s growing biotechnology ecosystem.”
Acubiosys focuses on developing natural and synthetic therapeutics for autoimmune diseases, chronic skin disorders and wound management.
Its research portfolio includes conditions such as psoriasis, atopic dermatitis, melasma and diabetic foot ulcers, which often require long-term treatment and continue to present significant clinical challenges.
The startup has commercialised two patented products manufactured in India in compliance with AYUSH regulations and Good Manufacturing Practices (GMP) standards.
BOCUGL is a nanotechnology-based topical formulation designed for the management of psoriasis, atopic dermatitis and melasma, while AZBECO is an advanced wound care formulation developed for chronic wounds and diabetic foot ulcers.
According to the startup, both products combine AI-assisted drug discovery with nanotechnology-enabled formulation development to improve therapeutic targeting.
The startup says it employed AI algorithms to analyse extensive botanical databases and used three-dimensional molecular modelling to virtually screen thousands of plant-derived compounds.
This process helped identify combinations with the greatest potential to target inflammatory pathways involved in chronic skin disorders and diabetic wound complications.
Nanotechnology was then used to encapsulate these bioactive compounds, enabling deeper penetration through the skin barrier and more targeted delivery to inflamed tissues.
Acubiosys has also stated that the underlying technologies have been filed for patent protection in India, China and the United States.
Stay tuned for more such updates on Digital Health News
